Baxter Healthcare

What Baxter Healthcare does

Baxter Healthcare is the Australian and New Zealand commercial and manufacturing presence of Baxter International Inc. (NYSE: BAX), a global medical technology and pharmaceutical company headquartered in Deerfield, Illinois, founded in 1931. The parent operates four primary franchises—hospital care, nutritional care, renal care, and surgical care—and employs approximately 37,500 people globally, with the Australian subsidiary supporting roughly 501-1,000 employees out of Toongabbie. Baxter is a Fortune 500 enterprise whose products are used in hospitals, clinics, renal centers, and home-care settings across more than 100 countries.

The company's product portfolio centers on sterile injectables, large-volume parenterals (LVPs), renal dialysis equipment and therapies, parenteral nutrition, surgical sealants and hemostats, and inhalation anesthetics. Baxter holds an estimated 18% share of the global LVP market, which is sized at approximately $12.54 billion. Its connected-care platform, SHARESOURCE, enables remote patient monitoring for home dialysis patients and represents the company's primary digital-health asset. Manufacturing is anchored in decades of sterile-process expertise and certified facilities regulated by the FDA, TGA, and other health authorities; in Australia, Baxter is the only onshore manufacturer of IV fluids.

Baxter monetizes through direct sales of medical devices and sterile pharmaceuticals to hospital systems, renal centers, and home-care patients, supplemented by government health-program procurement. Commercial relationships are governed by hospital formulary contracts, volume-based purchasing, and recurring consumables revenue streams tied to chronic therapies such as renal dialysis and parenteral nutrition. In Australia, the business model is reinforced by a AUD $40 million co-funded expansion of IV fluids manufacturing with the Australian Government, which deepens onshore supply positioning and aligns Baxter with national medical-security policy.

Name

Baxter Healthcare

Legal name

Baxter Healthcare Pty Ltd

Website

https://baxterhealthcare.com.au

Company type

Public

Founded year

1931

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Baxter Healthcare is the Australian and New Zealand subsidiary of Baxter International Inc. (NYSE: BAX), a global medical technology and pharmaceutical company supplying IV fluids, renal therapies, surgical products, and parenteral nutrition to hospitals, renal centers, and home-care patients.

Ownership category

akta.pro rank

Product category

Medical Devices and Hospital Products

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Specialty Care Pharmaceuticals (HLAIAAAB), Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE), Injectables & Specialty Medication Support (e.g., insulin, biologics) (HSABALAG), Compounding & Customized Medication Management Support (HSABALAL)

Keywords

• Medical device manufacturing
• Infusion therapy products
• Peritoneal dialysis systems
• Clinical nutrition solutions
• Surgical haemostatic products

Headquarters

HQ city

Toongabbie

HQ country

Australia

HQ region

Oceania

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Devices and Hospital Products: Sale of IV solutions, infusion systems, premixed drugs, pharmacy technologies, and surgical care products to hospitals and healthcare providers globally
2. Renal Care Products: Peritoneal dialysis solutions, automated PD systems, and dialysis therapies for kidney care patients
3. Nutritional Care Products: Clinical nutrition solutions including parenteral nutrition formulations, protein, carbohydrates, lipids, electrolytes, and vitamins
4. Pharmacy Compounding Services: TGA-licensed compounding services for chemotherapy and specialized medications for Australian hospitals

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Baxter Healthcare manufactures and supplies a diversified portfolio of medical devices, pharmaceuticals, and therapy products for hospitals and healthcare providers globally. Core product categories include hospital care (IV solutions, premixed drugs, infusion systems and intelligent pumps), nutritional care (parenteral and enteral clinical nutrition formulations), surgical care (haemostatic agents, tissue sealants, surgical patches), and renal care (peritoneal dialysis solutions, automated PD systems, and dialyzers). Baxter also operates TGA-licensed pharmacy compounding services in Australia for chemotherapy medications and supplies operating room equipment through its Hillrom integration.

Product overview

Baxter Healthcare operates as a diversified medical products company offering an integrated portfolio across hospital care, nutritional care, surgical care, and renal care. The company's product offerings span IV solutions and premixed drugs (VIAFLEX, MINI-BAG), infusion systems and pumps, clinical nutrition products (NUMETA, parenteral nutrition solutions), surgical care products (FLOSEAL, TISSEEL, HEMOPATCH, ARTISS haemostatic agents and sealants), renal care systems (HOMECHOICE, KAGUYA, AMIA with SHARESOURCE APD systems, THERANOVA dialyzers), and anesthesia products (SEVOFLURANE, DESFLURANE, CONTRAfluran gas capture). Following the Hillrom acquisition, Baxter expanded into operating room equipment including the TruPort boom systems. The portfolio also includes pharmacy automation technology (ExactaMix, Abacus) and remote patient monitoring capabilities through SHARESOURCE connectivity. Products are used across patient homes, hospitals, physician offices and other sites of care in more than 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Hillrom: Operating room and hospital care equipment brand, now part of Baxter following acquisition, later rebranded as Vantive.
• Vantive

Products and services

• VIAFLEX IV Containers First flexible plastic IV container brand, enabling closed-system intravenous infusions and reducing contamination risk for hospital IV therapy.
• MINI-BAG Plastic Containers Ready-to-use plastic containers for premixed drugs for hospital IV administration.
• IV Solutions and Premixed Drugs Comprehensive portfolio of intravenous solutions and premixed pharmaceutical products for hospital medication delivery, manufactured at Baxter's Australian-only onshore IV fluids facility.
• Infusion Systems and Intelligent Infusion Pumps Advanced infusion pumps and intelligent infusion technologies for safe and efficient medication delivery from pharmacy to bedside, designed to reduce preventable medication errors and infections.
• V-LINK IV Connector First IV connector with antimicrobial coating, supporting needleless IV therapy and infection reduction.
• INTERLINK IV Access System First needleless IV access system for safer IV therapy administration.
• NUMETA G13E Parenteral Nutrition Triple-chamber, ready-to-use parenteral nutrition system approved for preterm infants in Europe.
• Clinical Nutrition Products Parenteral and enteral nutrition solutions including proteins, carbohydrates, lipids, electrolytes, trace elements and vitamins for hospital and home clinical nutrition use.
• FLOSEAL Haemostatic Matrix Haemostatic matrix agent used to help address bleeding during and after surgical procedures.
• TISSEEL Fibrin Sealant First U.S.-approved fibrin sealant used for tissue sealing in surgical procedures.
• HEMOPATCH Sealing Hemostat Resorbable collagen-based pad that helps control bleeding in a variety of surgical scenarios.
• ARTISS Fibrin Sealant First commercially available slow-setting fibrin sealant used to adhere skin grafts in burn patients.
• HOMECHOICE Automated Peritoneal Dialysis System Automated peritoneal dialysis system for home-based renal therapy in end-stage renal disease patients.
• KAGUYA APD System Automated peritoneal dialysis system launched in Japan, designed to reflect local renal patient needs and demographics.
• AMIA with SHARESOURCE APD System First APD system with user-friendly features enabling home peritoneal dialysis therapy with remote connectivity to healthcare providers via SHARESOURCE platform.
• THERANOVA HDx Dialyzer Dialyzer with innovative membrane providing expanded hemodialysis therapy (HDx) for patients with end-stage renal disease.
• EXTRANEAL Peritoneal Dialysis Solution
• SEVOFLURANE Inhaled Anesthetic
• CONTRAfluran Gas Capture System
• Pharmacy Technology (ExactaMix and Abacus)
• ADVATE Recombinant Factor VIII
• FLEXBUMIN Albumin
• Hillrom TruPort Operating Room Boom Operating room boom system and equipment for surgical settings, integrated through the Hillrom acquisition.
• TGA-Licensed Pharmacy Compounding Services

Quantifiable outcome

• 200+ tonnes of PVC waste diverted from landfill annually through hospital recycling partnerships
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and supporting.

• Medical Technology Association of Australia (MTAA)coreStrategic or Co-development Partner · 14 May 2026Baxter partnered with MTAA to host the inaugural Australian Healthcare Manufacturing Leaders Network, bringing together senior leaders from Australia's medical manufacturing sector to discuss supply chain resilience, energy challenges, workforce recruitment, and AI in manufacturing.
• Epworth HealthCarecoreStrategic or Co-development Partner · 15 June 2017Epworth Richmond became the first hospital in Australia and New Zealand to expand Baxter's aluminium gas anaesthesia recycling program. Partnership diverts approximately 12 tonnes of hospital waste from landfill annually.
• Vinyl Council of Australia (VCA)coreStrategic or Co-development PartnerBaxter is a major sponsor of the PVC Recycling in Hospitals initiative launched by VCA in 2009. Program now operates in 100+ hospitals across Australia and New Zealand, diverting 200+ tonnes of PVC waste from landfill annually.
• AmericarescoreStrategic or Co-development PartnerHumanitarian aid partner for pre-positioning products during crises and ongoing needs in underserved communities. Partnered with Baxter International Foundation for disaster response including Hurricane Maria and Harvey.
• Direct ReliefcoreStrategic or Co-development PartnerHumanitarian aid partner working with Baxter to pre-position medical products for disaster response and support ongoing healthcare needs in underserved communities globally.
• American Red CrosscoreStrategic or Co-development PartnerBaxter International Foundation committed donations to American Red Cross for hurricane recovery efforts and humanitarian aid operations.
• TGA-Licensed Chemotherapy Compounders of Australia (TLCCA)coreStrategic or Co-development PartnerIndustry group representing TGA-licensed chemotherapy compounders (Baxter Healthcare, Slade Health, Wesley Pharmacy). Members compound more than 60% of cancer medicine infusions in Australia, including the vast majority in rural, regional and remote areas.
• Shawview ConsultingsupportingOthersPrepared research report for TLCCA demonstrating the value of TGA-licensed compounders to cancer patients and healthcare system, highlighting funding shortfall challenges.
• Mayo ClinicsupportingStrategic or Co-development PartnerResearch and clinical development collaboration announced for transformative healthcare innovations in therapeutic areas aligned with Baxter's focus.
• Ramot at Tel Aviv University/Tel Aviv Sourasky Medical CentersupportingStrategic or Co-development PartnerPartnership for research and clinical development collaboration to bring innovative healthcare solutions.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Fresenius Kabi: Fresenius Kabi is a direct competitor in IV solutions, infusion therapy, clinical nutrition, and injectable pharmaceuticals globally, competing head-to-head with Baxter in LVP and premixed drugs across hospital channels.
• B. Braun Melsungen: B. Braun competes directly with Baxter in IV solutions, infusion pumps, dialysis, and surgical products, with overlapping portfolio across hospital care and renal therapy internationally.
• Becton, Dickinson and Company (BD): BD overlaps with Baxter in infusion therapy, IV connectors, and drug delivery systems, particularly competing in infusion sets and needleless IV access devices like Baxter's INTERLINK and V-LINK.
• ICU Medical: ICU Medical is a focused competitor in IV infusion pumps, connectors, and closed-system transfer devices, directly competing with Baxter's infusion systems portfolio.
• Terumo Corporation: Terumo competes with Baxter in infusion systems, IV catheters, and hospital medical devices, particularly strong in the Asia-Pacific market where Baxter also operates.

Broad incumbents

• Fresenius Medical Care: Fresenius Medical Care is the global dialysis services and products leader, directly competing with Baxter's renal care portfolio (PD systems, dialyzers) and overlapping with the recently spun-off Vantive.
• Smith+Nephew: Smith+Nephew competes with Baxter's surgical care portfolio in haemostats, sealants, and tissue repair products, though it has a broader orthopedics and wound management focus.
• Medtronic: Medtronic is a broad incumbent in medical devices and supplies, overlapping with Baxter in surgical care and patient monitoring, and competing for hospital procurement share.
• Cardinal Health: Cardinal Health is a major medical products distributor and manufacturer, with overlapping distribution channels and competing IV/infusion offerings to Baxter's hospital customer base.

Others

• Vantive (Spun-off Kidney Care): Vantive was spun off from Baxter as an independent kidney care company, inheriting the renal therapies portfolio (PD systems, haemodialysis) and now competing as a former-sibling entity in renal care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@VantiveHealth
• Facebookfacebook.com/BaxterInternationalInc
• LinkedInlinkedin.com/showcase/baxter-australia-new-zealand

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baxter Healthcare